SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently the focus of intense investor scrutiny as shareholders, led by activist investor Shah Capital, escalate pressure on the board to address stagnant stock performance and executive compensation ahead of the upcoming June shareholder meeting. The community is actively debating the company's long-term potential, with bullish sentiment anchored in the proprietary Matrix-M adjuvant technology and potential oncology applications, while bearish voices remain focused on management's lack of transparency and failure to monetize key assets like the COVID-influenza combination vaccine.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is experiencing extreme volatility as traders react to conflicting reports surrounding a potential peace deal with Iran. While the community is deeply divided between those betting on an imminent diplomatic breakthrough to crush oil prices and those convinced that geopolitical tensions and physical supply constraints will continue to support an upward price trajectory, the conversation is dominated by accusations of market manipulation and distrust in the frequent, recycled headlines regarding negotiations.

Story is a purpose-built layer 1 blockchain designed specifically to onramp intellectual property (IP) to the blockchain and make it programmable.  Story tokenizes any type of IP; whether that’s an idea, an image, a real world asset, a song, an AI model, an NFT or anything in-between. By embedding usage terms, attribution, and royalty agreements directly into the blockchain, Story provides a transparent, decentralized solution for IP management. This enables IP holders to protect their work, collaborate on IP seamlessly, and unlock revenue opportunities in an AI-powered economy.

Story Protocol

Story Protocol's $IP.X token is experiencing significant community buzz driven by its role as AI-native infrastructure for programmable intellectual property, with traders heavily focused on its potential as a long-term AI data narrative. The community is actively debating the stock's volatility and its relationship with the public equity vehicle IPST, while many users speculate on the token's upside due to its circulating supply and emerging role in AI training data harvesting.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space Inc is seeing heightened trading activity and intense community debate as investors speculate on potential industry contracts, the impact of recent leadership transitions, and its strategic positioning ahead of the highly anticipated SpaceX IPO. While some investors are bullish on the company's supersonic platform and long-term space sector potential, others are actively highlighting risks related to cash burn, ongoing legal challenges, and the potential for share dilution.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is seeing significant market activity as investors weigh strong Q1 earnings results, featuring a 50% increase in EBITDA guidance, against ongoing volatility driven by Middle East geopolitical tensions and speculation over potential energy deals. While the community remains divided over the stock's sensitivity to war headlines versus its long-term fundamentals, many are actively monitoring insider activity and supply deficit projections as catalysts for a potential re-rating.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

The Dow Jones Industrial Average is hitting record highs as the broader market finds resilience, driven by strong earnings in AI and semiconductor sectors. Despite community concerns regarding high inflation, geopolitical tensions, and consumer pessimism, investors are debating whether this momentum reflects genuine economic strength or a vulnerable, bubble-like environment.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is trending as retail investors and traders speculate on its role in autonomous drone technology amid heightened global conflict and significant Pentagon budget allocations for unmanned systems. While the stock experiences high volatility driven by its low float and ongoing discussions regarding its military contracts, community sentiment remains sharply divided between bulls anticipating a massive short squeeze and critics citing concerns over thin revenue and overall valuation.

Nomad Foods Ltd. operates as a holding company, which manufactures and sells frozen foods for human consumption. The firm offers its products under the brands LUTOSA, la Cocinera, Birds Eye, Iglo, and Findus. The company was founded by Noam Gottesman and Sir Martin E. Franklin on April 1, 2014 and is headquartered in Woking, the United Kingdom.

Nomad Foods Limited

Nomad Foods is trending as investors weigh an internal leadership insider purchase against concerns regarding the impact of private label competition and broader input cost pressures. The community remains divided, with many highlighting the stock's discounted valuation and robust dividend, while others express frustration over stagnant price action and weak recent earnings performance.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing investor attention as community members debate its potential to decouple from broader market trends and retest key historical price levels. Much of the discourse focuses on long-term conviction regarding its utility as peer-to-peer electronic cash versus ongoing frustrations over its relative performance compared to other major digital assets.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding is surging following a strong quarterly report that featured a revenue beat and raised full-year guidance, fueling community excitement over its growing market share and premium brand positioning. Investors are particularly focused on the company's ability to maintain high margins and scale globally, leading to intense bullish sentiment and calls for further price appreciation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LLY Reports Third Phase III Win for Next-Generation Obesity Drug

Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.

HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry

Equity

The launch follows Novo Nordisk’s failure to pay a C$250 patent maintenance fee in Canada.

Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting

Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting PR...

Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss

Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.read more...

Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?

Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.

GSK Stock Declines 9% in a Month: Time to Buy, Hold or Exit?

GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.

Eli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now?

LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.

Could Viking Therapeutics Be the Next Eli Lilly?

Key PointsEli Lilly dominates the weight loss drug market and competes with fellow pharma giant Novo Nordisk...

Eli Lilly’s Retatrutide Delivers Bariatric-Style Weight Loss In Obesity Trial — Stock Rises Pre-Market

Eli Lilly said its retatrutide cleared a late-stage trial in patients with obesity, with some of them shedding a third of their body weight over 80 weeks.

Eli Lilly says next-generation weight loss drug clears crucial obesity trial

The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills...

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$8.81	--	--	N/A
Q1 '26	$6.97	$8.55	22.71%	BEAT
Q4 '25	$6.91	$7.54	9.10%	BEAT
Q3 '25	$5.69	$7.02	23.33%	BEAT
Q2 '25	$5.60	$6.31	12.70%	BEAT

LLY
Lilly(Eli) & Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Compact View

Latest LLY News

LLYLilly(Eli) & Co